Zandu Shareholders Choose Emami Group Over Parikh Family
This article was originally published in PharmAsia News
Executive Summary
Shareholders of India's Zandu Pharmaceuticals split with the controlling Parikh family and voted to sell their shares to a family rival, the Emami group that holds 24 percent of firm. The head of the stockholder group said shareholders feel the Emami should have had a role in the management the Parikh family controls. He said that with Emami involved in Zandu's operation, the shareholders would see a greater value for their stock, which the current management failed to provide. Zandu has not launched a significant new product for the past five years. (Click here for more
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.